Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Fixed Sequence Study in Healthy Participants to Assess the Effect of Multiple Doses of AZD2389 on the Pharmacokinetics of Midazolam, Caffeine, and Bupropion

NCT06973005 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06973005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06973005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Fixed Sequence Study in Healthy Participants to Assess the Effect of Multiple Doses of AZD2389 on the Pharmacokinetics of Midazolam, Caffeine, and Bupropion
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
May 8, 2025
Completion date
July 18, 2025
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced chronic liver disease, healthy participants